<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01795144</url>
  </required_header>
  <id_info>
    <org_study_id>12-1517</org_study_id>
    <nct_id>NCT01795144</nct_id>
  </id_info>
  <brief_title>Incretin Regulation of Insulin Secretion in Monogenic Diabetes</brief_title>
  <official_title>Incretin Regulation of Insulin Secretion in Monogenic Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Chicago</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to explore the mechanisms of metabolic control in monogenic
      diabetes patients treated with sulfonylurea medications.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Monogenic diabetes patients and healthy matched controls will be admitted to the University
      of Chicago Clinical Resource Center for a total of 4 nights. The following will take place on
      separate days:

        1. Oral Glucose Tolerance Test (OGTT): consume sugary drink and blood samples will be
           collected at multiple time points

        2. Isoglycemic glucose infusion (IGI) test: glucose will be infused via a vein in the arm
           and and blood samples will be collected at multiple time points

        3. OGTT during GLP-1 infusion

        4. IGI during Exendin-9 infusion
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">March 2017</completion_date>
  <primary_completion_date type="Actual">March 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incretin Effect</measure>
    <time_frame>Baseline</time_frame>
    <description>Directly calculated from the difference between oral and IV stimulated insulin secretion</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Monogenic Diabetes</condition>
  <arm_group>
    <arm_group_label>Healthy controls</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Healthy controls will be matched (age, gender, BMI) to monogenic diabetes subjects. Healthy controls will participate in the following:
OGTT
IGI
IGI with GLP-1 infusion
OGTT with Exendin 9-39 infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Monogenic diabetes</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Monogenic diabetes subjects will be matched (age, gender, BMI) to healthy controls. Monogenic diabetes subjects will participate in the following:
OGTT
IGI
IGI with GLP-1 infusion
OGTT with Exendin 9-39 infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GLP-1</intervention_name>
    <description>OGTT IGI IGI with GLP-1 infusion OGTT with Exendin 9-39 infusion</description>
    <arm_group_label>Healthy controls</arm_group_label>
    <arm_group_label>Monogenic diabetes</arm_group_label>
    <other_name>Glucagon-like peptide-1 (GLP-1)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exendin 9-39</intervention_name>
    <description>OGTT IGI IGI with GLP-1 infusion OGTT with Exendin 9-39 infusion</description>
    <arm_group_label>Healthy controls</arm_group_label>
    <arm_group_label>Monogenic diabetes</arm_group_label>
    <other_name>Glucagon-Like Peptide 1 (GLP-1) receptor antagonist</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Monogenic Diabetes Subjects:

        Inclusion Criteria:

          -  Diagnosis of monogenic diabetes

          -  Previously participated in US Neonatal Diabetes Registry (IRB 15617B) or Genetics of
             diabetes mellitus (IRB 6858)

          -  Age: 18 years +

        Exclusion Criteria:

          -  Pregnancy

          -  Acute medical illness or chronic conditions including: cardiac failure, renal
             insufficiency (estimated glomerular filtration rate &lt;50 ml/min), hepatic insufficiency
             (known cirrhosis or hepatitis), chronic obstructive pulmonary disease,
             gastrointestinal disorders causing malabsorption, anemia (Hct &lt; 36%), or uncontrolled
             hypertension

        Healthy Controls:

        Inclusion Criteria:

          -  Good general health

          -  Stable weight for 6 months

          -  Age: 18 years +

        Exclusion Criteria:

          -  Pregnancy

          -  Acute medical illness or chronic conditions including: cardiac failure, renal
             insufficiency (estimated glomerular filtration rate &lt;50 ml/min), hepatic insufficiency
             (known cirrhosis or hepatitis), chronic obstructive pulmonary disease,
             gastrointestinal disorders causing malabsorption, anemia (Hct &lt; 36%), or uncontrolled
             hypertension
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Siri Atma W Greeley, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Chicago</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 15, 2013</study_first_submitted>
  <study_first_submitted_qc>February 19, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 20, 2013</study_first_posted>
  <last_update_submitted>April 6, 2017</last_update_submitted>
  <last_update_submitted_qc>April 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucagon</mesh_term>
    <mesh_term>Glucagon-Like Peptide 1</mesh_term>
    <mesh_term>Incretins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>We do not plan to share data with other researchers.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

